The evolving role of catumaxomab in gastric cancer

Bibliography

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
   PubMed Web of Science ®Google Scholar
• Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: Eighteen-year experience at a single institution. J Gastrointest Surg 2005;9:718-25
   PubMed Web of Science ®Google Scholar
• Faycal J, Bessaguet C, Nousbaum JB, et al. Epidemiology and long term survival of gastric carcinoma in the French district of Finistere between 1984 and 1995. Gastroenterol Clin Biol 2005;29:23-32
   PubMed Web of Science ®Google Scholar
• Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer 2000;3:9-18
   PubMedGoogle Scholar
• Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-61
   PubMed Web of Science ®Google Scholar
• Jansen M, Büchin P, Dreuw B, et al. Prognostic factors for development of peritoneal carcinosis in stomach carcinoma. Chirurgie 2001;72:561-5
   Google Scholar
• D'Angelica M, Gonen M, Brennan F, et al. Patterns of recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-16
   PubMed Web of Science ®Google Scholar
• Siewert JR, Lordick F, Ott K, et al. Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies. Chirurg 2006;77:227-35
   PubMed Web of Science ®Google Scholar
• Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Japn J Surg 1981;11:127-39
   PubMedGoogle Scholar
• Gilly FN, Carry PY, Sayag AC. Regional chemotherapy with mitomycin C and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124-29
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58
   Web of Science ®Google Scholar
• Ito S, Nakanishi H, Kodera Y, et al. Prospective validation of quantitative CEA MRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer 2005;93:986-92
   PubMed Web of Science ®Google Scholar
• Feussner H, Omote K, Fink U, et al. Pretherapeutic laparoscopic staging in advanced gastric carcinoma. Endoscopy 1999;31:342-7
   PubMed Web of Science ®Google Scholar
• Gretschel S, Siegel R, Estevez-Schwarz L, et al. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 2006;93:1530-35
   PubMed Web of Science ®Google Scholar
• Nekarda H, Gess C, Stark M, et al. Immunocytochemically detected free peritoneal tumour cells (FPTC) are a strong prognostic factor in gastric carcinoma. Br J Cancer 1999;79:611-19
   PubMed Web of Science ®Google Scholar
• Katsuragi K, Yashiro M, Sawada T, et al. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer 2007;97:550-6
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-09
   PubMed Web of Science ®Google Scholar
• Lordick F, Jäger D. The current status and future of biochemotherapy in gastroesophageal cancers. Gastrointest Canc Res 2008; In press
   Google Scholar
• Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005;8:78-85
   PubMedGoogle Scholar
• Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med 2007;357:1863-5
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Van de Velde C, Roth A, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008;44:182-94
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20
   PubMed Web of Science ®Google Scholar
• Arnold D, Lordick F. Systemic treatment of peritoneal metastases. Chirurg 2007;78:1117-22
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer– pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43
   PubMed Web of Science ®Google Scholar
• Glockzin G, Ghali N, Lang SA, et al. Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy. Chirurg 2007;78:1100-10
   PubMed Web of Science ®Google Scholar
• Scaringi S, Kianmanesh R, Sabate JM, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intra-peritoneal-chemotherapy: a single western center experience. Eur J Surg Oncol 2008; published online 28 January 2008, doi:10.1016/j.ejso.2007.12.003
   Google Scholar
• Litvinov SV, Velders MP, Bakker HA, et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46
   PubMed Web of Science ®Google Scholar
• Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712
   PubMed Web of Science ®Google Scholar
• Went P, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35(1):122-8
   PubMed Web of Science ®Google Scholar
• Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008;68(1):143-51
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-35
   PubMed Web of Science ®Google Scholar
• Munz M, Kieu C, Mack B, et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Li W, Sutterwala S, et al. A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 2004;173:1023-32
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Peipp M, Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans 2002;30(4):507-11
   PubMed Web of Science ®Google Scholar
• Segal DM, Qian J-H, et al. Targeting of anti-tumor responses with bispecific antibodies. Immunobiol 1992;185:390-402
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 2004;7(2):233-42
   PubMed Web of Science ®Google Scholar
• Kufer Pl, Lutterbüse R, et al. A revival of bispecific antibodies. Trends Biotechnol 2004;22(5):238-44
   PubMed Web of Science ®Google Scholar
• Mack M, Riethmueller G, et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995;92:7021-5
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-43
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Kufer P, et al. Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 2003;5(4):413-9
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6
   PubMed Web of Science ®Google Scholar
• Lindhofer H, Mocikat R, Steipe B, et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-25
   PubMed Web of Science ®Google Scholar
• Ruf P, Gires O, et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. BJC 2007;1-7
   Google Scholar
• Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunctional bispecific (αCD3 × αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004;25:841-8
   PubMed Web of Science ®Google Scholar
• Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. BJC 2000;83(2):261-66
   PubMed Web of Science ®Google Scholar
• Riesenberg R, Buchner A, Pohla H, et al. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEp-CAM × αCD3). J Histochem Cytochem 2001;49:911-7
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mayer A, Gires O, et al. TNF-α contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 2001;21:3499-504
   PubMed Web of Science ®Google Scholar
• Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advaced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905
   PubMed Web of Science ®Google Scholar
• Parsons SL, Kutarska E, Koralewski P, et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: rResults of a phase II/III study [abstract]. J Clin Oncol 2007;25(18S):5520
   Google Scholar
• Parsons SL, Muarwa PX, Kolesnik OO, et al. Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study [abstract]. Proc Gastrointest Cancer Symp 2008;102
   Google Scholar
• Stroehlein M, Gruetzner K, Tarbichi A, et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis [abstract]. J Clin Oncol 2006;24(18S):2544
   PubMed Web of Science ®Google Scholar
• Sebastian M, Passlick B, Friccius-Quecke H, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a Phase I study. Cancer Immunol Immunother 2007;56:1637-44
   PubMed Web of Science ®Google Scholar
• Stroehlein M, Schemanski O, Jaeger M, et al. Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with advanced gastric, colon, and pancreatic cancer: a pilot phase I study [abstract]. Proc Gastrointest Cancer Symp 2008;120
   Google Scholar
• Heiss M, Berdov B, Roman I, et al. Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: a phase II study. Ann Oncol 2008; in press
   Google Scholar
• de Boer C, van Krieken J, Janssen-Van Rhijn C, et al. Expression of EpCAM in normal regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201-06
   PubMed Web of Science ®Google Scholar
• Ding W, Yin X. Dissection of the multiple mechanisms of TNF-α-induced apoptosis in liver injury. J Cell Mol Med 2004;8(4):445-54
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
   PubMed Web of Science ®Google Scholar